Welcome to our dedicated page for Lexicon Pharmaceuticals SEC filings (Ticker: LXRX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) SEC filings page on Stock Titan provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. These filings offer detailed information on Lexicon’s biopharmaceutical operations, financial condition, capital-raising activities and risks associated with its pipeline in heart failure, hypertrophic cardiomyopathy, neuropathic pain, obesity, diabetes and related indications.
Investors can review current reports on Form 8-K, where Lexicon discloses material events such as quarterly financial results, at-the-market equity offering arrangements, Nasdaq listing status updates and key business developments. For example, recent 8-K filings describe an Open Market Sale Agreement with Jefferies LLC, legal opinions related to potential share sales, and communications regarding compliance with Nasdaq’s minimum bid price requirement and transfer to The Nasdaq Capital Market.
In addition to 8-Ks, users can locate Lexicon’s annual reports on Form 10-K and quarterly reports on Form 10-Q (when available through EDGAR), which typically contain audited financial statements, management’s discussion and analysis, detailed descriptions of products such as sotagliflozin (INPEFA®), pilavapadin (LX9211) and LX9851, as well as information on licensing agreements with partners like Viatris and Novo Nordisk. Proxy materials and other filings may address executive compensation, governance and shareholder matters.
Stock Titan enhances these documents with AI-powered summaries that highlight key points from lengthy reports, helping users quickly understand major changes in revenue sources, R&D priorities, collaboration structures, risk factors and capital structure. Real-time updates from EDGAR ensure that new Lexicon filings, including any Form 4 insider transaction reports, become accessible promptly, while AI-generated overviews make complex regulatory language more approachable for both individual and institutional investors.
LEXICON PHARMACEUTICALS director Raymond Debbane reported an open-market purchase of company stock. He bought 2,000 shares of common stock at a price of
The filing also lists indirect holdings in Lexicon Pharmaceuticals common stock through various affiliated investment entities, including 1,538,462 shares held by Avicenna Life Sci Master Fund LP and related parties, 7,362,368 shares by Invus Public Equities, L.P. and related parties, 5,451,204 shares by Invus US Partners, LLC and related parties, and 35,402,689 shares by Invus, L.P. and related parties.
Lexicon Pharmaceuticals director Raymond Debbane reported an open-market purchase of 100,000 shares of common stock at
Lexicon Pharmaceuticals director Raymond Debbane reported buying 150,000 shares of common stock in open-market transactions. On February 19, he purchased 50,000 shares at a weighted average price of
After these purchases, his directly owned stake increased to 1,804,186 common shares. The filing also reports additional common stock positions as indirectly owned through entities including Avicenna Life Sci Master Fund LP, Invus Public Equities, L.P., Invus US Partners, LLC, and Invus, L.P.
Artal Participations S.a r.l., a major holder in Lexicon Pharmaceuticals (LXRX), reported receiving an additional 41,289.58 shares of Lexicon’s Series B Convertible Preferred Stock at
Each share of this preferred stock will automatically convert into 50 shares of common stock once shareholders approve the conversion and other stated conditions are satisfied; until then, the shares are not convertible. After this transaction, Artal Participations S.a r.l. holds a total of 408,434.70 shares of Series B Convertible Preferred Stock indirectly, with related Artal entities and their principals disclaiming beneficial ownership except for any pecuniary interest described.
Lexicon Pharmaceuticals director Raymond Debbane reported open-market purchases of 268,497 shares of common stock over three days. He bought 57,952 shares on February 13 at a weighted average price of about $1.3093, 76,857 shares on February 17 at about $1.3082, and 133,688 shares on February 18 at about $1.32 per share, all in multiple transactions within narrow intraday price ranges. After these purchases, his directly held stake increased to 1,654,186 shares of Lexicon common stock. The filing also lists indirect ownership positions held through Avicenna Life Sci Master Fund LP and several Invus-affiliated entities, with millions of additional shares reported as indirectly owned.
Lexicon Pharmaceuticals insider compensation grant: SVP of Human Resources Wendy McDermott received equity awards on February 12, 2026. She acquired 250,200 restricted stock units, each representing a contingent right to one share of common stock, all held directly after the grant.
She was also granted stock options for 375,300 shares of common stock at an exercise price of $1.37 per share, also held directly. The restricted stock units vest in three equal installments each February 28 in the three years after the grant year, while the options vest 25% on the first anniversary of grant and then 1/48th per month with continued service.
Lexicon Pharmaceuticals reported that SVP, Partnerships & Corporate Strategy Rachel Yap Martens received new equity awards on February 12, 2026. She was granted 193,740 restricted stock units, each representing one future share of common stock, and a stock option for 290,620 shares at an exercise price of $1.37 per share.
The restricted stock units vest in three equal installments on February 28 of each of the three years after the grant year. The stock option vests 25% on the first anniversary of grant, then in equal monthly installments over the following three years, subject to continued service.
Lexicon Pharmaceuticals executive Craig B. Granowitz, SVP and Chief Medical Officer, reported new equity awards. On February 12, 2026, he received 346,610 restricted stock units, each representing one share of common stock, and a stock option for 519,920 shares with a $1.37 exercise price.
The restricted stock units vest in three equal installments on February 28 of each of the three years following the grant year. The option vests 25% on the first anniversary of grant, with the remaining 75% vesting in equal monthly installments over the next 36 months, conditioned on continued service.
Lexicon Pharmaceuticals granted equity awards to senior vice president of discovery Suma Gopinathan. On February 12, 2026, she acquired 238,450 restricted stock units, each representing one share of common stock, and a stock option for 357,680 shares at an exercise price of $1.37 per share.
The RSUs vest in three equal installments on February 28 of each of the three years following the grant year. The option vests 25% on the first anniversary of grant, then 1/48th of the shares each month of continued service until fully vested by February 12, 2036.
Lexicon Pharmaceuticals, Inc. reported equity awards to senior vice president Lisa DeFrancesco. On February 12, 2026, she received 257,530 restricted stock units, each representing a right to one share of common stock, and 386,300 stock options with a $1.37 exercise price.
The restricted stock units vest in three equal installments on February 28 of each of the three years after the grant year. The stock options vest 25% on the first anniversary of grant, with the remaining portion vesting monthly over the following three years, contingent on continued service.